Dataset opportunity
Kardium — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Kardium, usable for Diagnostic AI and Computer Vision.
Score
70.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Diagnostics Market = $1.2B in 2023, CAGR 24.6%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Kardium holds a unique Medical Imaging Dataset derived from its proprietary 122-electrode mapping and ablation system. This dataset contains highly detailed, sensitive patient electrophysiological records, including intracardiac electrograms and 3D heart maps, which are crucial for training and validating advanced Diagnostic AI models for complex cardiac arrhythmias like atrial fibrillation.
The global AI in diagnostics market was valued at $1.2 billion in 2023 and is projected to grow at a CAGR of 24.6%, demonstrating immense business value. Despite access complexities due to patient privacy and medical device regulations, this dataset's proprietary data is exceptionally rare. Its specialized origin provides a significant competitive advantage for AI developers aiming to create next-generation diagnostic tools in the high-growth cardiology sector. ⚠ Diligence (valuable data, access to negotiate): Data involves sensitive patient electrophysiological records; Subject to strict medical device regulations and clinical trial privacy; Proprietary data is generated via specialized 122-electrode hardware · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Kardium possesses a rare, proprietary dataset originating from formal clinical trials for Atrial Fibrillation (AF) treatment. The data uniquely combines medical imaging with high-definition, synchronous sensor data from its 122-electrode diagnostic and ablation system. For companies developing diagnostic AI, this multimodal dataset is a critical asset for training next-generation algorithms for AF detection, procedural guidance, and outcome prediction, targeting the fast-growing $1.2B AI in Diagnostics market.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is extremely high, driven by the explosive 24.6% CAGR of the AI in diagnostics market as companies seek proprietary data to gain a competitive edge.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — This medical device company's core business is selling the Globe System for treating atrial fibrillation; the high-definition cardiac mapping data generated during procedures is a valuable, unmonetized by-product, making it an ideal target. Issues: The company is well-funded and on a rapid growth trajectory towards a potential IPO, which might reduce its interest in a data partnership compared to a smaller
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>Johnson & Johnson MedTech unveiled its Ottava surgical robotics system at the July 2026 Society of Robotic Surgery (SRS) annual meeting after winning FDA de novo authorization. “These teams have built a category-defining, soft-tissue surgical robot, and our regulatory pathway is a testament to that. There is no precedent here,” J&J MedTech Global Head of…</p> <p>The post <a href="https://www.medicaldesignandoutsourcing.com/jnj-robotics-rd-ottava-folding-arms-soothing-sounds-and-haptics-capability/">J&J’s robotics R&D head discusses Ottava’s fo”
- “<figure><div><img src="https://imgproxy.divecdn.com/Z4XM1PqUx6TE2yKkipcT7bU4fjBke63Nffmy96QnOj8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9pbS0yMDE4MTAwNTAwMXNoc18xODAwMDAwMDA1ODE0NzMxLmpwZw==.webp" /></div></figure><p>The deal to provide a range of imaging and therapeutic technologies to Cleveland Clinic extends the partners’ longtime relationship and follows a recent 10-year pact between Siemens Healthineers and Mayo Clinic.</p>”
- “<div> <a href="https://nordiclifescience.org/johnson-johnson-bets-on-in-vivo-car-t-with-sail-biomedicines/"><img alt="Johnson & Johnson bets on in vivo CAR-T with Sail Biomedicines" height="150" src="https://nordiclifescience.org/wp-content/uploads/2023/10/iStock-1404269031-e1698045567576.jpg" title="Handshake in digital futuristic style. The concept of partnership, collaboration or teamwork. Vector illustration with light effect and neon" width="300" /></a> </div> <p> Johnson & Johnson has entered a strategic collaboration with Sail Biomedicines to advance in vivo CAR-T therapies ”
IoT / sensor data
This evidence indicates high-resolution time-series data from the device's 122 electrodes, capturing detailed cardiac mapping and contact sensing information valuable for training automated diagnostic AI models.
Medical records / imaging
This confirms the dataset includes medical images and associated records gathered under rigorous clinical trial protocols (PULSAR & GLOBAL studies), providing a regulatory-grade foundation for validating AI diagnostic tools.
Industrial data
This points to synchronous time-series data detailing the therapeutic procedure itself, including ablation energy and temperature, which is crucial for developing AI that can predict treatment efficacy and optimize procedural outcomes.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
A teaser is generated for each dataset opportunity. The full report is available on unlock.
From the marketplace
Explore live data opportunities
Smartct — Downloadable Data Asset Opportunity
View opportunity →healthcareFusixbiotech — Industrial Operations Dataset Opportunity
View opportunity →healthcareMeditek — Maintenance Logs Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Is Your Data Worth Money?3 min read
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read